Key result
Nebulized rFVIIa rapidly controls diffuse alveolar hemorrhage in a patient with SLE.
Why the study?
Does inhaled recombinant activated factor VII improve hemostasis and gas exchange in a patient with diffuse alveolar hemorrhage secondary to systemic lupus erythematosus?
Case Report (n=1)
No
Does inhaled recombinant activated factor VII improve hemostasis and gas exchange in a patient with diffuse alveolar hemorrhage secondary to systemic lupus erythematosus?
Answers are grounded in this paper and cite their sources.
Inhaled recombinant activated factor VII administered via a jet nebulizer may be an effective and novel route for treating diffuse alveolar hemorrhage in patients with systemic lupus erythematosus.
Diffuse alveolar hemorrhage (DAH) is a serious pulmonary complication in patients with autoimmune diseases who are undergoing chemotherapy or have had hematopoietic stem cell transplantation. The use of recombinant factor VIIa (rFVIIa) to treat the acute phase of DAH by endobronchial bronchoscopy has been shown to have a significant clinical impact on the survival and evolution of these patients. We report a clinical case of a patient with DAH secondary to systemic lupus erythematosus (SLE) who was treated with rFVIIa administered using a jet nebulizer, obtaining an adequate hemostatic effect with immediate control of DAH and a significant improvement in gas exchange.
No takes yet. Share an insight, caveat, or question.
Esper et al. (2014) conducted a case report in Diffuse alveolar hemorrhage secondary to systemic lupus erythematosus (n=1). Recombinant activated factor VII (rFVIIa) was evaluated on Control of diffuse alveolar hemorrhage. Administration of recombinant activated factor VII via a jet nebulizer achieved rapid hemostatic control and improved gas exchange in a patient with diffuse alveolar hemorrhage secondary to systemic lupus erythematosus.
Synapse has enriched 10 related papers. Consider them for comparative context: